The purpose of this study is to evaluate the safety and efficacy of solbinsiran in lowering triglycerides and other lipid measures compared to placebo in participants with severe hypertriglyceridemia. Participants will receive two subcutaneous injections.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change from Baseline in Triglycerides
Timeframe: Baseline, Weeks 16-24 (Time-Average)
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or